Concept of breathlessness
The terms dyspnoea ('diffi cult breathing'), breathlessness and shortness of breath are often used interchangeably. Breathlessness is the term most often used by patients. Other patient descriptors, such as air hunger, increased work of breathing, chest tightness and a feeling of suffocation, have been disappointing in identifying specifi c pathophysiologies to allow targeted intervention. Temporal patterns of breathlessness, including continuous or episodic breathlessness, with or without apparent triggers, are a current topic of research 1 in the hope that such discrimination will inform future management choices.
Breathlessness is a symptom that can only be described and interpreted by the patient. 2 It should be considered as distinct from the traditionally observed physiological parameters that physicians use when assessing for respiratory compromise, such as respiratory rate, oxygen saturation and the use of accessory muscles.
[ 
Prevalence and impact
Breathlessness is common in patients with advanced lifethreatening illnesses of all types. The prevalence reaches 90% in cancer, 95% in chronic obstructive pulmonary disease (COPD), 88% in cardiac failure, 80% in end-stage renal disease and 85% in advanced neurological disease. 3 Both prevalence and intensity increase as death approaches.
Breathlessness causes signifi cant suffering to patients and to carers, profoundly disrupting day-to-day functioning and causing social isolation. It can engender helplessness, be linked to thoughts of impending death and be a major trigger for hospital admission.
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Mechanism of refractory breathlessness
Unlike the normal 'physiological' feeling of being out of breath generated in health by physical exertion (eg climbing stairs at speed), the experience of breathlessness in advanced disease is more than a simple symptom, rather a complex set of interactions between physical, psychological and emotional factors that are further modulated by an individual's past experiences, expectations and fears for the future.
It is all too easy to underestimate the experience of breathlessness and the associated suffering. The sensation of breathlessness is generated when higher cortical centres perceive what the respiratory system can provide as inadequate or unsustainable to meet the body's requirements, and the patient may perceive a signifi cant threat to survival (Fig 1) .
Recent functional neuroimaging studies have shown that breathlessness, irrespective of cause or stimulus, activates distinct areas in the limbic system. 4 This region is rich in opioid receptors and probably generates the conscious awareness of breathlessness and the associated sensation of unpleasantness.
Assessment
Breathlessness is a subjective symptom that cannot easily be quantifi ed, and there is no commonly agreed assessment tool. 5 Few parameters measured in pulmonary function laboratories heart failure but respond to treatment with signifi cant improvement in symptoms. Conversely, treating a pleural effusion will not benefi t a dying patient. Potentially reversible causes of breathlessness include pulmonary embolus, infection, arrhythmia, anaemia and ascites.
Evidence base for non-pharmacological treatment
Two Cochrane reviews and four systematic reviews published since 2008 [7] [8] [9] have recommended non-pharmacological approaches for intractable breathlessness associated with advanced disease. These are summarised in Table 1 .
Evidence base for pharmacological treatments

Opioids
Opioids are the mainstay of pharmacological intervention for breathlessness and multiple randomised controlled trials (RCTs) and systematic reviews 11, 12 have shown signifi cant reductions in breathlessness with the use of oral or parenteral opioids in patients with advanced disease. Most studies have used morphine, but a class effect is assumed.
are representative of real life, and they are too burdensome for use in patients with advanced disease states. The assessment of breathlessness should refl ect patients' reporting of both severity and affective components.
When assessing any response to intervention, consideration must refl ect patient-relevant outcomes. Success, therefore, may be a reduction in intensity of breathlessness, a reduction in psychological distress, an increase in activity levels or a reduction in hospital admissions.
In patients with advanced disease, there is little potential of returning to a non-breathless state. There may be a delay in the patient developing confi dence in an intervention before achieving mastery of breathlessness and increased performance. Small objective increments (5.5 mm on a 100 mm visual analogue scale) can translate into meaningful improvement for patients. 6 
Treatment
Ensure that treatment for the underlying disease is optimised in the context of disease trajectory, performance status and patients' wishes. Patients with advanced cancer can develop Opioids are proposed both to reduce the spontaneous respiratory motor response to hypercapnia and hypoxia and to modulate the central processing such that perceptual sensitivity to breathlessness is diminished. 13 Important gaps remain in the knowledge base regarding variability in the degree of opioid responsiveness and tolerability between patients. Recent work suggests that younger patients and those who experience the greatest severity of breathlessness are most likely to benefit.
Fears around safety are common but unsubstantiated. Several studies have shown no evidence of signifi cant opioid-induced respiratory depression or hastened death, such that their use is now recommended in advanced respiratory disease. 14 Expert opinion regarding the initiation of opioids for breathlessness lies in two camps: commencement of longacting morphine (10 mg daily) 12 vs more gradual titration using low-dose, short-acting morphine. 15 Local practice in our hospital favours the second approach, starting with low-dose, short-acting morphine (1-2 mg twice daily plus 1-2 mg as required) and with judicious weekly uptitration to the minimum effective dose that improves tolerability of breathlessness and limits opioid-related adverse effects. Side effects, especially constipation, should be anticipated and managed proactively. Recent studies looking at the longer term benefi ts and acceptability of low-dose opioids for patients with COPD are encouraging. 15 For patients already established on opioids for pain, an increment of 25% above baseline is recommended.
Oxygen
Long-term oxygen therapy improves both survival and quality of life for patients with COPD with signifi cant chronic hypoxia. Oxygen is often prescribed for palliation of breathlessness in the setting of other advanced disease, but the evidence base does not support this practice in the absence of hypoxia. A Cochrane review and a large RCT comparing oxygen and room air via nasal cannula showed no additional symptomatic benefi t with oxygen over room air in non-hypoxic patients with malignant and nonmalignant aetiologies. [16] [17] [18] Movement of air across the face may be benefi cial, and this can readily be achieved using a fan. Opioids have been found to be signifi cantly better than oxygen in reducing breathlessness. 13 Short-burst oxygen supplementation may prevent desaturation during exercise but may not relieve breathlessness. Careful assessment of symptomatic benefi t on an individual basis is recommended.
Anxiolytics
Signifi cant interplay between breathlessness and anxiety is often present, making it diffi cult for patients and clinicians to distinguish the primary source of distress.
Benzodiazepines are often used for breathlessness, but the evidence base is sparse. Recent reviews identified only a non-significant trend for cancer-and non-cancer-related breathlessness. 19 Two more-recent RCTs support a modest benefit of midazolam, particularly in combination with morphine. 20 In practice, a therapeutic trial of low-dose benzodiazepine (lorazepam 0.5-1.0 mg sublingually as required) would be cautiously recommended when anxiety is prominent and breathlessness is not amenable to non-pharmacological interventions and opioids.
Antidepressants with anxiolytic properties, such as mirtazapine and citalopram, may have a role alongside nonpharmacological interventions (Box 1).
Conclusion
Breathlessness is the subjective experience of not being able to breathe comfortably. It is a common and distressing multi-dimensional symptom. An interdisciplinary approach that considers both non-pharmacological and pharmacological measures can substantially reduce its impact for patients (Fig 2) . ■ 
Key points
Severity of breathlessness is unrelated to measurable parameters or disease status
No single intervention is likely to relieve refractory breathlessness; aim to change perception and experience of breathlessness
The most effective regimens for palliation of breathlessness include concurrent use of non-pharmacological and pharmacological interventions
Opioids can safely reduce the subjective sensation of intractable breathlessness
Oxygen may correct hypoxia, and movement of air palliates breathlessness KEY WORDS: Breathlessness, multi-professional approach, opioids, subjective, symptom mastery ■
